{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:32:44Z","timestamp":1794105164040,"version":"4.8.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"26","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipoprotein(a) [Lp(a)] is a significant, genetically determined contributor to the risk of atherosclerotic cardiovascular disease (ASCVD), which remains the leading cause of mortality worldwide despite successes in the management of LDL cholesterol. Lipoprotein(a) possesses increased atherogenicity, contributing to residual cardiovascular risk. Elevated Lp(a) levels affect a substantial proportion of the population, rendering this a potentially high-impact therapeutic target, but currently available lipid-lowering agents and lifestyle interventions have minimal impact on lowering Lp(a), and lipoprotein apheresis is the sole effective\u2014but impractical\u2014method to significantly reduce Lp(a). Recent advances in Lp(a)-targeted therapies, notably nucleic acid-based approaches (e.g. antisense oligonucleotides and small interfering RNAs) and a small molecule inhibitor of Lp(a) synthesis, demonstrated substantial and often durable Lp(a)-lowering effects in Phase II trials. Phase III trials of these agents are now underway to examine the impact of lowering Lp(a) levels on atherosclerotic cardiovascular disease outcomes, and their results may transform the landscape of cardiovascular risk reduction and management for patients with elevated Lp(a). This review summarizes existing lipid-lowering therapies\u2019 limited effects on Lp(a), provides an update on the array of emerging therapeutics and their safety and efficacy, and discusses ongoing Phase III trials as well as other potential benefits of Lp(a)-lowering, such as slowing progression of calcific aortic valve stenosis.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag092","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:09:10Z","timestamp":1769515750000},"page":"3375-3385","source":"Crossref","is-referenced-by-count":13,"title":["Lipoprotein(a)-lowering therapies: a promising future"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-5709","authenticated-orcid":false,"given":"Jingwen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-3339","authenticated-orcid":false,"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University Faculty of Medicine , Cinnah Caddesi 24\/11 \u00c7ankaya, 06690 Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026070619572411900_ehag092-B1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/eurheartj\/ehab892","article-title":"European Society of Cardiology: cardiovascular disease statistics 2021","volume":"43","author":"Timmis","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B2","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2026070619572411900_ehag092-B4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2026070619572411900_ehag092-B5","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B6","first-page":"46:3875\u201384","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1210\/clinem\/dgab734","article-title":"Lipoprotein(a) levels at birth and in early childhood: the COMPARE study","volume":"107","author":"Strandkj\u00e6r","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070619572411900_ehag092-B9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jama.1996.03540070040028","article-title":"Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study","volume":"276","author":"Bostom","year":"1996","journal-title":"JAMA"},{"key":"2026070619572411900_ehag092-B10","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B11","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"JACC"},{"key":"2026070619572411900_ehag092-B13","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.jacc.2024.08.070","article-title":"Oxidized phospholipids and calcific aortic valvular disease","volume":"84","author":"Bhatia","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572411900_ehag092-B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"2026070619572411900_ehag092-B16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamacardio.2023.3548","article-title":"Concordance of a high lipoprotein(a) concentration among relatives","volume":"8","author":"Reeskamp","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026070619572411900_ehag092-B17","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1172\/JCI117292","article-title":"The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate","volume":"93","author":"Rader","year":"1994","journal-title":"J Clin Invest"},{"key":"2026070619572411900_ehag092-B18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/MOL.0000000000000823","article-title":"Understanding the ins and outs of lipoprotein (a) metabolism","volume":"33","author":"Boffa","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"2026070619572411900_ehag092-B19","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026070619572411900_ehag092-B20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1042\/BCJ20240037","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"481","author":"Boffa","year":"2024","journal-title":"Biochem J"},{"key":"2026070619572411900_ehag092-B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"Chemello","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B22","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/01.CIR.96.5.1612","article-title":"Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo","volume":"96","author":"Biemond","year":"1997","journal-title":"Circulation"},{"key":"2026070619572411900_ehag092-B23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J Lipid Res"},{"key":"2026070619572411900_ehag092-B24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jacl.2022.02.004","article-title":"Quantifying the contribution of lipoprotein(a) to all apoB containing particles","volume":"16","author":"Chilazi","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2026070619572411900_ehag092-B25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572411900_ehag092-B26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572411900_ehag092-B27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026070619572411900_ehag092-B28","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in lipoprotein(a) levels among patients with coronary heart disease","volume":"85","author":"Barkas","year":"2025","journal-title":"JACC"},{"key":"2026070619572411900_ehag092-B29","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026070619572411900_ehag092-B30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2026070619572411900_ehag092-B31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"JACC"},{"key":"2026070619572411900_ehag092-B32","first-page":"46:4762-75","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol\u2013mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"2026070619572411900_ehag092-B34","doi-asserted-by":"publisher","first-page":"120420","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B35","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.atherosclerosis.2019.07.021","article-title":"Statins and Lp(a)\u2014the plot thickens.","volume":"289","author":"Enkhmaa","year":"2019","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"key":"2026070619572411900_ehag092-B38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jacl.2024.12.014","article-title":"Characteristics and outcomes of patients with and without statin-associated muscle symptoms treated with bempedoic acid in the CLEAR outcomes trial","volume":"19","author":"Laufs","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026070619572411900_ehag092-B39","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metab\u2014Clin Exp"},{"key":"2026070619572411900_ehag092-B40","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"The AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"The HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.clinthera.2019.06.012","article-title":"Serious adverse effects of extended-release niacin\/laropiprant: results from the heart protection study 2-treatment of HDL to reduce the incidence of vascular events (HPS2-THRIVE) trial","volume":"41","author":"Haynes","year":"2019","journal-title":"Clin Ther"},{"key":"2026070619572411900_ehag092-B43","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026070619572411900_ehag092-B45","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572411900_ehag092-B46","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HP53\/TIMI55-REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B47","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026070619572411900_ehag092-B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B49","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572411900_ehag092-B50","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B51","doi-asserted-by":"publisher","first-page":"e011781","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026070619572411900_ehag092-B52","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.3390\/jcm11237249","article-title":"Comparison of current international guidelines for the management of dyslipidemia","volume":"11","author":"Aygun","year":"2022","journal-title":"J Clin Med"},{"key":"2026070619572411900_ehag092-B53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"JACC"},{"key":"2026070619572411900_ehag092-B54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B55","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026070619572411900_ehag092-B56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"2026070619572411900_ehag092-B57","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J Clin Med"},{"key":"2026070619572411900_ehag092-B58","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"2026070619572411900_ehag092-B59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B60"},{"key":"2026070619572411900_ehag092-B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026070619572411900_ehag092-B62","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2026070619572411900_ehag092-B63","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"2026070619572411900_ehag092-B65","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The off-treatment effects of olpasiran on lipoprotein(a) lowering","volume":"84","author":"O \u2018Donoghue Michelle","year":"2024","journal-title":"JACC"},{"key":"2026070619572411900_ehag092-B66","author":"Amgen"},{"key":"2026070619572411900_ehag092-B67","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1161\/ATVBAHA.124.319483","article-title":"Lipoprotein(a) in the year 2024: a look back and a look ahead","volume":"44","author":"Tsimikas","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572411900_ehag092-B68","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"2026070619572411900_ehag092-B69","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/genes13030436","article-title":"The effect of dicer knockout on RNA interference using various dicer substrate small interfering RNA (DsiRNA) structures","volume":"13","author":"Song","year":"2022","journal-title":"Genes (Basel)"},{"key":"2026070619572411900_ehag092-B70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.athplu.2024.09.004","article-title":"Lipoprotein(a) and the atherosclerotic burden\u2014should we wait for clinical trial evidence before taking action?","volume":"58","author":"Fichtner","year":"2024","journal-title":"Atheroscler Plus"},{"key":"2026070619572411900_ehag092-B71","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran\u2014a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070619572411900_ehag092-B72","author":"Eli Lilly and Company"},{"key":"2026070619572411900_ehag092-B73","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"2026070619572411900_ehag092-B74","doi-asserted-by":"publisher","first-page":"100723","DOI":"10.1016\/j.jlr.2024.100723","article-title":"Measuring lp(a) particles with a novel isoform-insensitive immunoassay illustrates efficacy of muvalaplin","volume":"66","author":"Swearingen","year":"2025","journal-title":"J Lipid Res"},{"key":"2026070619572411900_ehag092-B75","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"2026070619572411900_ehag092-B76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0009-8981(87)90110-0","article-title":"Free and apo B-associated lpa-specific protein in human serum","volume":"164","author":"Gries","year":"1987","journal-title":"Clin Chim Acta"},{"key":"2026070619572411900_ehag092-B77","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1161\/01.ATV.16.8.905","article-title":"Urinary excretion of apo(a) fragments. Role in apo(a) catabolism","volume":"16","author":"Kostner","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026070619572411900_ehag092-B78","doi-asserted-by":"publisher","first-page":"44624","DOI":"10.1038\/srep44624","article-title":"Somatic genome editing with CRISPR\/Cas9 generates and corrects a metabolic disease","volume":"7","author":"Jarrett","year":"2017","journal-title":"Sci Rep"},{"key":"2026070619572411900_ehag092-B79","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"2026070619572411900_ehag092-B80","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtm.2022.10.009","article-title":"LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: a proof-of-concept study","volume":"27","author":"Doerfler","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026070619572411900_ehag092-B81","doi-asserted-by":"publisher","first-page":"A17013","DOI":"10.1161\/circ.148.suppl_1.17013","article-title":"Abstract 17013: CTX320: an investigational in vivo CRISPR-based therapy efficiently and durably reduces lipoprotein (a) levels in non-human primates after a single dose","volume":"148","author":"Morrow","year":"2023","journal-title":"Circulation"},{"key":"2026070619572411900_ehag092-B82"},{"key":"2026070619572411900_ehag092-B83","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"2026070619572411900_ehag092-B84","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070619572411900_ehag092-B85","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070619572411900_ehag092-B86","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12933-024-02389-7","article-title":"Causal associations between insulin and lp(a) levels in Caucasian population: a Mendelian randomization study","volume":"23","author":"Lejawa","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2026070619572411900_ehag092-B87","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","article-title":"Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen General Population Study","volume":"349","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"2026070619572411900_ehag092-B88","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jacasi.2024.08.008","article-title":"Lp(a) and accelerated progression of aortic stenosis","volume":"4","author":"Tsimikas","year":"2024","journal-title":"JACC Asia"},{"key":"2026070619572411900_ehag092-B89","author":"Novartis Pharmaceuticals"},{"key":"2026070619572411900_ehag092-B90","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jacl.2023.09.016","article-title":"Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease","volume":"17","author":"Panza","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2026070619572411900_ehag092-B91","doi-asserted-by":"publisher","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels international declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3375\/66888514\/ehag092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/26\/3375\/66888514\/ehag092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:57:30Z","timestamp":1783382250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/26\/3375\/8482286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":91,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2026,2,13]]},"published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag092","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,7]]},"published":{"date-parts":[[2026,2,13]]}}}